Bio-Rad Laboratories Files Routine 8-K Disclosure

TL;DR

**Bio-Rad filed a routine 8-K, nothing major to see here.**

AI Summary

Bio-Rad Laboratories, Inc. filed an 8-K on February 21, 2024, under Regulation FD Disclosure. The filing indicates an event reported on February 21, 2024, and pertains to their common Class A and Class B members. This filing is a routine disclosure and does not contain specific financial figures or major corporate actions like acquisitions or earnings.

Why It Matters

This filing is a standard disclosure, indicating compliance with SEC regulations but not signaling any immediate significant operational or financial changes for Bio-Rad Laboratories.

Risk Assessment

Risk Level: low — The filing is a standard Regulation FD disclosure without any specific adverse events or material changes reported.

Key Players & Entities

• BIO-RAD LABORATORIES, INC. (company) — Registrant
• February 21, 2024 (date) — Date of earliest event reported and filing date
• 1-7928 (string) — Commission File Number
• Delaware (string) — State of incorporation
• 94-1381833 (string) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange

Filing Documents

• bio-20240221.htm (8-K) — 40KB
• 0000012208-24-000015.txt ( ) — 204KB
• bio-20240221.xsd (EX-101.SCH) — 3KB
• bio-20240221_def.xml (EX-101.DEF) — 15KB
• bio-20240221_lab.xml (EX-101.LAB) — 30KB
• bio-20240221_pre.xml (EX-101.PRE) — 16KB
• bio-20240221_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

ITEM 7.01 Regulation FD Disclosure. Bio-Rad Laboratories, Inc. ("Bio-Rad") hereby provides the following update on information disclosed under the heading "Investment in Sartorius AG" in Part 1 Item 1 of Bio-Rad's Form 10-K for the year ended December 31, 2023 that was filed on February 16, 2024 relating to Bio-Rad's investment in Sartorius AG. The update relates to Sartorius AG's financial results for the year ended December 31, 2023 that were disclosed by Sartorius AG on February 16, 2024. Investment in Sartorius AG The following summarizes certain financial data of Sartorius as of and for the year ended December 31, 2023, (in millions). December 31, 2023 (1) Current assets 1,956.9 Non-current assets 7,798.5 Current liabilities 1,330.0 Non-current liabilities 5,667.9 Equity 2,757.4 Year Ended December 31, 2023 (1) Sales revenue 3,395.7 Gross profit on sales 1,567.1 Earnings before interest and taxes (EBIT) 503.9 Net profit 290.0 Cash flow from operating activities 853.6 Cash flow from investing activities (2,823.3) Cash flow from financing activities 2,165.7 1. As disclosed in Sartorius AG's consolidated financial statements for the year ended December 31, 2023, prepared in accordance with the International Financial Reporting Standards (IFRS), the International Financial Reporting Interpretations Committee (IFRIC) Standards, and the International Accounting Standards Board (IASB) as required to be applied by the European Union, and based upon information publicly disclosed by Sartorius. Bio-Rad does not assume, and by way of referencing the financial data of Sartorius above shall not be deemed to assume, any responsibility or liability for any errors or omissions in the information publicly disclosed by Sartorius. Refer to Sartorius' 2023 Annual Report for further details, which can be found at https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relatio ns. The Sartorius website and any information disclosed the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: February 21, 2024 By: /s/ Timothy S. Ernst Timothy S. Ernst Executive Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR